{"organizations": [], "uuid": "c3b3c457f008cdfc9c5368314efcf31ba99bacb1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/30/pr-newswire-nordic-nanovector-asa-publishes-annual-report-for-2017.html", "country": "US", "domain_rank": 767, "title": "Nordic Nanovector ASA Publishes Annual Report for 2017", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-30T19:35:00.000+03:00", "replies_count": 0, "uuid": "c3b3c457f008cdfc9c5368314efcf31ba99bacb1"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/30/pr-newswire-nordic-nanovector-asa-publishes-annual-report-for-2017.html", "ord_in_thread": 0, "title": "Nordic Nanovector ASA Publishes Annual Report for 2017", "locations": [], "entities": {"persons": [{"name": "malene brondberg", "sentiment": "none"}, {"name": "nanovector", "sentiment": "none"}], "locations": [{"name": "oslo", "sentiment": "none"}, {"name": "norway", "sentiment": "none"}], "organizations": [{"name": "ano", "sentiment": "none"}, {"name": "nhl", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "OSLO, Norway, April 30, 2018 /PRNewswire/ -- The Board of Directors of Nordic Nanovector ASA (OSE: NANO) has approved the company's Annual Report for 2017 including the complete 2017 Annual Accounts with notes. The report is attached to this announcement and available on Nordic Nanovector ASA's website in the section Investor Relations/Reports and presentations/Annual Reports.\nFor further information, please contact:\nMalene Brondberg, VP Investor Relations and Corporate Communications\nCell: +44-7561-431-762\nEmail: ir@nordicnanovector.com\nAbout Nordic Nanovector:\nNordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37 -targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com\nForward-looking statements\nThis announcement contains certain forward-looking statements and forecasts based on uncertainty, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms \"anticipates\", \"assumes\", \"believes\", \"can\", \"could\", \"estimates\", \"expects\", \"forecasts\", \"intends\", \"may\", \"might\", \"plans\", \"should\", \"projects\", \"targets\", \"will\", \"would\" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statement. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in these forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's products candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.\nThis information is subject to a duty of disclosure pursuant to Section 5-12 of the Securities Trading Act.\nThis information was brought to you by Cision http://news.cision.com\nhttp://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa-publishes-annual-report-for-2017,c2509680\nThe following files are available for download:\nhttp://mb.cision.com/Public/9819/2509680/b5741a08f8bd40bf.pdf\nAnnual report 2017\nView original content: http://www.prnewswire.com/news-releases/nordic-nanovector-asa-publishes-annual-report-for-2017-300639092.html\nSOURCE Nordic Nanovector", "external_links": ["http://news.cision.com/", "http://www.nordicnanovector.com/", "http://www.prnewswire.com/news-releases/nordic-nanovector-asa-publishes-annual-report-for-2017-300639092.html", "http://mb.cision.com/Public/9819/2509680/b5741a08f8bd40bf.pdf", "http://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa-publishes-annual-report-for-2017,c2509680"], "published": "2018-04-30T19:35:00.000+03:00", "crawled": "2018-04-30T20:20:18.000+03:00", "highlightTitle": ""}